These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21390007)

  • 21. Legal and social aspects of biotechnology in Poland.
    Twardowski T
    Acta Biochim Pol; 2005; 52(3):III-V. PubMed ID: 16475253
    [No Abstract]   [Full Text] [Related]  

  • 22. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 23. Merv Turner.
    Turner M
    Nat Biotechnol; 2011 Mar; 29(3):186. PubMed ID: 21390005
    [No Abstract]   [Full Text] [Related]  

  • 24. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 25. Academic industry relationships in biotechnology: a primer on policy and practice.
    Campbell EG; Blumenthal D
    Cloning; 2000; 2(3):129-36. PubMed ID: 16218849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GSK moves on Sirtris.
    Sipp D
    Nat Biotechnol; 2008 Jun; 26(6):595. PubMed ID: 18536662
    [No Abstract]   [Full Text] [Related]  

  • 27. Selling out.
    Martin JF
    Nat Biotechnol; 2010 Apr; 28(4):315-7. PubMed ID: 20383912
    [No Abstract]   [Full Text] [Related]  

  • 28. Advice for partnering with pharma.
    Howard K
    Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
    [No Abstract]   [Full Text] [Related]  

  • 29. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

  • 30. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 31. University spin-offs: opportunity or challenge?
    Peng X
    Nat Mater; 2006 Dec; 5(12):923-5. PubMed ID: 17139301
    [No Abstract]   [Full Text] [Related]  

  • 32. China steps towards international M&A.
    Jia H; Louët S
    Nat Biotechnol; 2005 Feb; 23(2):159. PubMed ID: 15696134
    [No Abstract]   [Full Text] [Related]  

  • 33. Millennium ends Takeda's US shopping spree.
    Sipp D
    Nat Biotechnol; 2008 Jun; 26(6):593-5. PubMed ID: 18536661
    [No Abstract]   [Full Text] [Related]  

  • 34. More than the sum of their parts? Clustering is becoming more prevalent in the biosciences, despite concerns over the sustainability and economic effectiveness of science parks and hubs.
    Rinaldi A
    EMBO Rep; 2006 Feb; 7(2):133-6. PubMed ID: 16452923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Massachusetts: Mass effect.
    Savage N
    Nature; 2016 Sep; 537(7618):S18-9. PubMed ID: 27580137
    [No Abstract]   [Full Text] [Related]  

  • 36. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 37. Life sciences firms cheer unlocking of National Health Service.
    Hodgson J
    Nat Biotechnol; 2011 Jul; 29(7):560. PubMed ID: 21747369
    [No Abstract]   [Full Text] [Related]  

  • 38. Study critiques corporate control of trials.
    Niiler E
    Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 40. Lost opportunities.
    Phan P; Wong D
    Nature; 2017 Dec; 552(7683):S18. PubMed ID: 29220004
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.